Why Is HEARTFLOW INC (HTFL) Stock Up Today?

HTFL stock is moving sharply higher today, with the shares reaching a session high of $51.00, up from an opening price of $47.81. The surge follows late-breaking data from a government-funded Dutch trial presented at the European Society of Cardiology (ESC) conference. The trial showed that Heartflow’s FFRCT analysis significantly reduces unnecessary invasive heart procedures. Specifically, the study found that invasive angiography was performed in 43% of patients using FFRCT, compared to 61% in the control group, with no significant safety differences reported.

The trial involved 528 patients and demonstrated that revascularization rates remained consistent at 20% between the groups. These findings reinforce the clinical value of Heartflow’s noninvasive diagnostic technology, which has previously shown strong results in other trials. The results come amid a backdrop of recent positive developments for the company, including strong Q2 financial results and upgraded guidance. Analysts at Canaccord Genuity and Morgan Stanley have also raised their price targets for the stock, maintaining positive outlooks.

What The Data Shows: Intraday volume has surged to 2.2 million shares, or 1.4 times the 3-month daily average, as the stock trades near its 52-week high of $51.19. Over the past 8 sessions, the stock has risen 2.1%, from $46.80 to $47.76. Recent insider activity has seen multiple sales by top executives, including the CEO and Chief Medical Officer, totaling $7.3 million in the last 90 days. The stock also printed 50 fresh 52-week highs and 5 fresh 52-week lows on August 31.

What To Watch: While the company has no scheduled earnings release, investors will continue to monitor coverage breadth and analyst reactions to the latest clinical data.